Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia

Meng Li and Ari M. Melnick

Summary: In this issue of Blood Cancer Discovery, Yan and colleagues discovered that mitochondrial deacylase, SIRT5, is required in AML cells to support mitochondrial oxidative phosphorylation, maintain redox homeostasis, and drive glutaminolysis. The new SIRT5 inhibitor, NRD167, can efficiently target SIRT5 in AMLs at micromolar range and may constitute a novel therapeutic approach to improve clinical outcomes of patients with AML.

In this issue of Blood Cancer Discovery, Yan and colleagues carried out a cancer-focused shRNA screen searching for essential genes in primary human AML cells (4). SIRT5 scored as one of the top essential candidates from this screen of around 1,300 genes. One important reason why SIRT5 was selected in this study is because Sirt5 knockout mice have mild phenotypes, suggesting that strict SIRT5 dependency may be only related to disease (AML) phenotypes. SIRT5 is a member of the sirtuin protein family and localizes specifically in the mitochondria along with SIRT3 and SIRT4. Sirtuins were originally defined as NAD-dependent protein deacetylases. However, these three mitochondrial sirtuins possess different enzymatic activities due to structural differences in their enzyme pockets. SIRT5 is a protein deacetylase that removes malonyl, succinyl, and glutaryl groups, while SIRT3 works as a protein deacetylase and SIRT4 is mainly an ADP-ribosyltransferase (5).

SIRT5 was reported to play distinct roles in tumorigenesis in a context-dependent manner, but no study had explored its function in AML. Therefore, Yan and colleagues first validated that the dependency of SIRT5 was ubiquitous in most primary AML cases and AML cell lines, but not in normal cord blood cells. Depletion of SIRT5 in SIRT5-dependent AML cell lines eradicated leukemia cells in vivo but had minimal effect on SIRT5-independent cases. Bone marrow cells from SIRT5 knockout mice manifested delayed transformation into AML induced by canonical AML driver–mutant proteins, including MLL-AF9, BCR-ABL, and FLT3-ITD. These data are intriguing, as they indicate that SIRT5 functions as a novel form of non-oncogene addiction in many AMLs. Indeed, genetic profiling data showed that SIRT5 dependency in AML cells was not associated with any known somatic mutation. In contrast, Yan and colleagues found that depletion of mitochondrial DNA killed all SIRT5-dependent AML lines, while mitochondria were dispensable in SIRT5-independent lines. Thus, the dependence of SIRT5 was associated with AML’s strong dependence on mitochondria. Similarly, BCL2 was previously shown to sustain mitochondrial oxidative phosphorylation in AML cells regardless of specific somatic mutations. Therefore, SIRT5 represents another mechanism enabling mitochondrial activity to support AML progression. Previous proteomics study showed that SIRT5 knockout induced hypersuccinylation in hundreds of mitochondrial proteins including many enzymes in the tricarboxylic acid (TCA) cycle.
SOD2 activity induced by SIRT3 deacetylation is required for each other’s loss of function in specific biological conditions. Findings showing that SIRT5 and SIRT3 can compensate for AML cells from ROS damage. This is consistent with recent evidence that SIRT5 and SIRT3 may coordinate together to protect against oxidative stress. It is still a mystery how SIRT5 depletion induces ROS production because no direct connection was discovered instead of SOD1, could partially rescue the SIRT5 knockdown effects. It is still a mystery how SIRT5 depletion induces ROS production because no direct connection was discovered between SIRT5 and SOD2. However, as it is known that SIRT3 can deacetylate SOD2 to increase its activity, it is possible that SIRT5 and SIRT3 may coordinate together to protect AML cells from ROS damage. This is consistent with recent findings showing that SIRT5 and SIRT3 can compensate for each other’s loss of function in specific biological conditions. SOD2 activity induced by SIRT3 deacetylation is required for aged HSCs to maintain their self-renewal ability. AMLs can thus hijack the activity of SIRT3 to support oxidative phosphorylation and SOD2 to facilitate chemoresistance.

On the other hand, the authors found that SIRT5-dependent AML cells more efficiently converted glutamine into glutamate as a source for anaerobic metabolism. This enhanced glutaminolysis may be the result of SIRT5 desuccinylating its substrate glutaminase (GLS). Untargeted metabolomic profiling accordingly showed that SIRT5 loss of function resulted in reduced abundance of TCA cycle and amino acid metabolites. These metabolic changes may be explained by the diverse deacetylase activities of SIRT5. Yan and colleagues observed increased protein succinylation, malonylation, and even acetylation in SIRT5-depleted AML cells, which indicates that these posttranslational modifications may have an important functional impact on the respective metabolic enzymes. CMK cells (SIRT5-dependent) showed more profound increase of acetylation than KG1a cells (SIRT5-independent), so it might be possible to characterize SIRT5’s deacetylated targets as a putative biomarker to determine the dependency of SIRT5 in AML cases. Such effects on metabolism-associated posttranslational modifications have also been documented as being regulated by SIRT3. Proteomics studies showed that lysine acetylation and succinylation are most frequently observed in mitochondrial proteins, and some proteins can be regulated by both SIRT5 and SIRT3.
modifications (8, 9). It is unknown whether different acylation moieties (acetyl, malonyl, succinyl, and glutaryl) affect one another’s abundance in the mitochondria and hence induce different or nuanced impact on mitochondrial activity. Yan and colleagues observed that loss of SIRT5 in AML cells also affects mitochondrial protein acetylation, which may indicate further potential functional overlap with SIRT3 in maintaining AML mitochondrial functions. It would be of interest to further compare the role of both sirtuins to further understand their relative contributions to AML stem cell functions.

Several small-molecule inhibitors targeting sirtuin family proteins have been developed in recent years. However, it is relatively difficult to design tool compounds that achieve both high efficacy and sirtuin selectivity that have favorable pharmacologic properties. One route to achieve this involves the design of mechanism-based inhibitors using a thioacyllysine peptide as substrate to form a stalled S-alkylamidate intermediate that blocks substrates from engaging the sirtuins catalytic pocket. This strategy was used to successfully generate inhibitors to selectively target SIRT2 and SIRT3 in vitro and in vivo (10). Similarly, Yan and colleagues started from a mechanism-based inhibitor/prodrug designed to target SIRT5, yielding a compound that could inhibit SIRT5 in vitro with an IC\textsubscript{50} of 110 nmol/L. After the authors modified the SIRT5 inhibitor to increase its cell permeability, the final compound, NRD167, could kill SIRT5-dependent AML cells at micromolar concentrations but exhibited less effect against SIRT3-independent AMLs or normal cord blood cells. Furthermore, NRD167 treatment phenocopied the inhibition of oxidative phosphorylation by SIRT5 shRNAs (Fig. 1C). NRD167 treatment also tends to prolong the survival in mice engrafted with primary human AML cells. Another SIRT5 inhibitor, DK1-04 (11), was reported to have an IC\textsubscript{50} in vitro of 340 nmol/L. NRD167 and DK1-04 shared a similar mechanism of action in forming stalled covalent intermediates with SIRT5. DK1-04e was also effective against breast cancer xenografts in vivo, so it would be interesting to compare the two SIRT5 inhibitors in future AML studies. SIRT5 requires mitochondrial NAD to exert its enzyme activity. A recent work from Jones and colleagues discovered that NAD metabolism is a crucial metabolic checkpoint helping refractory and relapsed AML cells escape from venetoclax treatment (3). It would be interesting to know whether SIRT5 may play a role in this NAD-dependent resistance to venetoclax. Along these lines, as SIRT5 and BCL2 may intersect in regulating leukemia stem cell mitochondrial metabolism functions, it would be interesting to test whether drugs such as NRD167 and venetoclax could be used in combination for greater eradication of AML stem cells.

**Authors’ Disclosures**

A.M. Melnick reports grants from Janssen and Sanofi, personal fees from Epizyme, Constellation, Bristol-Myers Squibb, and Exo-Therapeutics, and other support from KDAC outside the submitted work, as well as a patent for 8635-01-US issued. No disclosures were reported by the other author.

Published first April 10, 2021.

**REFERENCES**

Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia

Meng Li and Ari M. Melnick


Updated version

Access the most recent version of this article at:

doi: 10.1158/2643-3230.BCD-21-0026

Cited articles

This article cites 10 articles, 1 of which you can access for free at:

http://bloodcancerdiscov.aacrjournals.org/content/2/3/198.full#ref-list-1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link

http://bloodcancerdiscov.aacrjournals.org/content/2/3/198.

Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.